falsefalse

Dr. Iacovelli on Key Takeaways from the ARIES Trial in Urothelial Cancer

Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses the key takeaways of the phase 2 ARIES trial (NCT03891238) in urothelial cancer.

    The ARIES trial evaluated first-line avelumab (Bavencio) in patients with metastatic and locally advanced urothelial cancer who were PD-L1 positive and unfit for cisplatin-based chemotherapy.

    Findings from this study suggested avelumab demonstrated activity in urothelial cancer, Iacovelli says. Moreover, avelumab has a tolerable safety profile, Iacovelli adds.

    Notably, patients with urothelial cancer who are ineligible for cisplatin-based chemotherapy tend to have a poor prognosis, and they are generally frailer, Iacovelli explains. These patients should be managed with immunotherapy and should be further studied in future clinical trials, Iacovelli concludes.


    x